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DOI 10.1016/j.ccr.2012.02.013SUMMARYAcute lymphoblastic leukemias (ALLs) are characterized by multistep oncogenic processes leading to cell-
differentiation arrest and proliferation. Specific abrogation of maturation blockage constitutes a promising
therapeutic option in cancer, which requires precise understanding of the underlyingmolecular mechanisms.
We show that the cortical thymic maturation arrest in T-lineage ALLs that overexpress TLX1 or TLX3 is due to
binding of TLX1/TLX3 to ETS1, leading to repression of T cell receptor (TCR) a enhanceosome activity and
blocked TCR-Ja rearrangement. TLX1/TLX3 abrogation or enforced TCRab expression leads to TCRa rear-
rangement and apoptosis. Importantly, the autoextinction of clones carrying TCRa-driven TLX1 expression
supports TLX ‘‘addiction’’ in TLX-positive leukemias and provides further rationale for targeted therapy
based on disruption of TLX1/TLX3.INTRODUCTION
Acute leukemias are characterized by a multistep oncogenic
process leading to the maturation arrest and malignant transfor-
mation of a hematopoietic precursor (Pui et al., 2004). Under-Significance
Targeted therapy, including abrogation of a block to cell matu
has so far proved difficult to implement, partly due to theirmulti
tumor suppressors have emerged as tangible candidates. A
defines a large subgroup of leukemias with a cortical thymic d
block is due to failure to rearrange TCRa and that sustained T
the acquisition of a variety of additional genetic abnormalities.
geted therapy based on disruption of TLX1/TLX3 in this T-ALLstanding of the molecular mechanisms leading to this block in
maturation is a prerequisite for the development of therapeutic
approaches aiming to unblock differentiation of leukemic
blasts (Look, 1997). Transcription factors (TFs) that are involved
in the control of cell differentiation or proliferation of normalration, is a promising therapeutic approach in leukemias but
oncogenic nature, especially in T-ALLwhere fewoncogenes/
mong T-ALL patients, aberrant expression of TLX1/TLX3
evelopmental arrest. Our data show that this differentiation
LX expression is required for leukemic maintenance despite
Taken together, our results provide further rationale for tar-
subset.
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TLX-ETS-Mediated TCRa Block of Maturation in T-ALLhematopoietic progenitors and are deregulated in acute
leukemias could represent promising therapeutic targets, as
described for the treatment of PML-RARA+ acute promyelocytic
leukemia (Degos, 1992).
Human T-lymphocyte ontogeny is a hierarchical process
occurring in the thymus in which the ordered somatic recombi-
nation of V, D, and J gene segments at the TCRd, TCRg,
TCRb, or TCRa loci determine the development into either gd
or ab T cell lineages (Dik et al., 2005; Spits, 2002) (Figure S1 avail-
able online). Progressive lineage restriction and acquisition of
T cell potential following migration from the bone marrow to
the thymus involve successive differentiation steps defined by
the acquisition of a number of surface molecules, including
CD5, CD1a, CD34, CD3, CD4, and CD8. TCRd rearrangement
is the first to occur, at the CD5+, CD1a CD4/8 double-negative
(DN) stage, followed by concurrent TCRg and TCRb rearrange-
ments coinciding with CD1a expression (Dik et al., 2005). While
the occurrence of productive TCRg and TCRd rearrangements
will determine the assembly of a gd receptor, a complete produc-
tive TCRb gene rearrangement will first allow surface expression
of a pre-TCR complex formed by the assembly of the TCRb chain
with a pre-Ta (pTa) invariant chain. Pre-TCR surface expression,
referred to as the b-selection process, is marked by arrest of
TCRb gene rearrangements and extensive cellular expansion.
It is mandatory to the progression of ab T cell precursors to the
CD4/CD8 double-positive (DP) cortical thymic cell stage, and
to the initiation of Va-Ja rearrangements (von Boehmer et al.,
1998). The TCRd locus being interspersed between the Va and
Ja segments, it is deleted out during Va-Ja recombination,
marking definitive engagement to the TCRab lineage. The ‘‘fron-
tiers’’ of the TCRd locusmay be regarded as being defined by the
50dRec and 30cJa elements, as all 50V and 30Ja gene segments
located outside these segments contribute to the functional
repertoire of ab T cells, including a few Va/Vd gene segments
that occasionally recombine with Jd gene segments (Krangel
et al., 1998). The TCRa rearrangement is a highly regulated
process, in which the TCRa enhancer (Ea) plays a primary role
(Bassing et al., 2003; Sleckman et al., 1997). Themolecular regu-
lation of Ea has been intensively studied (Hawwari and Krangel,
2005; Ho et al., 1989, 1990; McMurry and Krangel, 2000). The
minimal Ea core contains binding sites for three TFs, LEF-1,
RUNX1/AML1, and ETS1, which have been demonstrated to
be crucial for the transcriptional and cis-chromatin opening
activities of the so-called Ea enhanceosome (Giese et al.,
1995; Ho et al., 1989, 1990; Roberts et al., 1997).
T-ALL is a heterogeneous group of acute leukemias that are
arrested at various stages of normal thymic-cell differentiation
(Asnafi et al., 2003; Ferrando et al., 2002). Recognized T-ALL
oncogenic events include transcriptional activation of proto-
oncogenes, submicroscopic deletion of tumor suppressor
genes, and activation of the Notch1 pathway by NOTCH1 or
FBXW7 mutations (Aifantis et al., 2008). Among the various
T-ALL oncogenic alterations reported to date, TCR chromo-
somal translocations represent a recurrent oncogenic hallmark
of T-ALL (Cauwelier et al., 2006). Such translocations are gener-
ally believed to result from illegitimate V(D)J recombination
events that lead to the ectopic activation of oncogenes owing
to their relocation to the vicinity of potent cis-activating elements
within the involved TCR locus.564 Cancer Cell 21, 563–576, April 17, 2012 ª2012 Elsevier Inc.Overexpression of the orphan homeobox (HOX) proteins TLX1
and TLX3 represents the most frequent oncogenic event due to
chromosomal translocation in human T-ALL. TLX1 and TLX3
belong to theNKL subtype of HOXproteins. They contain a highly
conserved homeodomain (HD) that is known to be involved in
DNA and protein-protein interactions (Holland et al., 2007). In
T-ALL, both proteins are associated with specific gene expres-
sion profiles, a variety of additional genetic mutations, and differ-
entiation arrest at an early cortical stage of thymocytematuration
(Asnafi et al., 2004; Ferrando et al., 2002; Soulier et al., 2005).
Physiological expression of TLX1 and TLX3 is restricted to
embryonic development (Roberts et al., 1994; Shirasawa et al.,
2000), and no specific function of these genes in the T cell
lineage has been reported. Transgenic expression of human
TLX1 in mice induces an initial DN2 thymic block followed by
development of aneuploid T-ALL, mitotic checkpoint defects,
clonal TCRb rearrangements, a mostly cortical phenotype, and
a transcriptional profile similar to that observed in human
TLX1+ T-ALLs (De Keersmaecker et al., 2010). Corresponding
data are not yet available for TLX3, and the molecular mecha-
nisms underlying the observed developmental arrest in TLX1+
and TLX3+ T-ALLs remain elusive. We therefore undertook to
determine if and how TLX oncoproteins were linked to the
cortical thymic maturation arrest and what the impact of this
specific oncogenic function was on the initiation, development,
and maintenance of TLX+ T-ALLs.
RESULTS
TLX-Expressing T-ALLs Undergo VbDJb
Rearrangements but Display a Strong Bias
against Va-Ja Joints
A series of 230 T-ALLs were analyzed by real-time quantitative
PCR (RT-qPCR) for TLX1 and TLX3 expression. Applying
a TCR-based classification (Asnafi et al., 2003), 52 cases were
immature/uncommitted (surface (s) and cytoplasmic (c) TCRb
negative) and comprised IM0, IMd, and IMg subtypes (i.e.,
harboring, respectively, a germline configuration of all three
TCRb, d, and g loci, or a TCRd- or TCRg-rearranged locus, and
in some cases with an incompletely rearranged DJb locus);
103 cases were early cortical IMb/pre-ab and included IMb
and pre-ab subtypes (displaying VbDJb rearrangement and,
respectively, either a cTCRb or sTCR/cTCRb+ phenotype);
39 cases were sTCRab+; and 36 were sTCRgd+ (of which 20
also harbored a VbDJb-rearranged locus) (Table S1). Sixty-five
cases (28%) demonstrated TLX1 or TLX3 overexpression in
a mutually exclusive manner, and were henceforth referred to
as TLX+. Among TLX+ T-ALLs, all but one demonstrated at least
one VbDJb rearrangement; this included all TCRgd-expressing
cases (p < 0.001). Strikingly, none of the TLX+ samples displayed
a sTCRab+ phenotype, implying a uniform arrest in maturation at
an early cortical cell stage, prior to TCRa chain expression.
To determine whether the lack of TCRab expression in TLX+
T-ALLs was due to a defect in TCRa gene rearrangement or
TCRa chain expression, we analyzed, by Southern blotting and
DNA PCR, the status of the TCRd locus (which is deleted during
Va-to-Ja rearrangement) in 52 phenotypically matched IMb/
pre-ab T-ALLs (Asnafi et al., 2003), including 26 TLX+ (13 each
of TLX1 and TLX3) and 26 TLX T-ALLs (Table 1). Remarkably,
Table 1. TCRd Allele Rearrangement Status in IMb/Pre-ab TLX+
(n = 26) and TLX– (n = 26) T-ALL
IMb/Pre-ab T-ALL TCRd
Allelic Status TLX+ (n = 52) TLX (n = 52) p Value
GL, D-D, D-J or V-D 6 (11%) 5 (10%) ns
VDJ 37a (71%) 10b (19%) < 0.001
Deletion 3 (6%) 31 (60%) < 0.001
Translocated alleles 6 (11%) 6 (11%) ns
See also Table S1 and Figures S1 and S2.
aIncludes 15 atypical rearrangements (seven Va-Jd, three Vd8-Jd1, one
Vd6-Jd2, and one Vd7-Jd1) and 20 typical rearrangements using conven-
tional Vd1–3 segments.
bOnly one atypical rearrangement (Vd5-Jd1).
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TLX-ETS-Mediated TCRa Block of Maturation in T-ALL49 of 52 (94%) TCRd alleles were readily detected (i.e., were not
deleted) in TLX+ T-ALLs compared with 21 of 52 (40%) TCRd
alleles in TLX controls (p < 0.001). The TCRd locus may be
regarded as defined by the 50dRec and 30cJa elements (Fig-
ure S1), as all functional 50V and 30Ja gene segments located
outside these limits were found to potentially undergo rearrange-
ment in abT cells, including a few Va/Vd gene segments that
occasionally recombine with Jd gene segments (Krangel et al.,
1998). Thorough analysis of TCRd rearrangements in TLX+
versus TLX samples by PCR cloning and sequencing demon-
strated that the majority of the former samples harbored
complete VdDJd joints with, intriguingly, a high proportion
involving TCRd-specific, distal 50 Vd gene segments (Vd4–6),
dual TCRd/a (Vd7, Vd8), or even TCRa-specific (Va) gene
segments, accounting for a total of 41% of the VDJ rearranged
alleles compared to only 10% in TLX cases (Table 1). Overall,
TLX1+ and TLX3+ T-ALL samples displayed no significant differ-
ence in their profiles of TCRd locus rearrangement (data not
shown). These results, coupled with the lower level of TCRd
locus deletion and absence of TCRab expression, strongly argue
for a block in V-to-Ja rearrangement in TLX+ versus TLX T-ALL
samples. As Ea is required for optimal Va-to-Ja recombination
(Bassing et al., 2003; Sleckman et al., 1997), we hypothesized
that Ea activity could be compromised during the course of
TLX+ T-ALL leukemic transformation in humans.
TLX+ T-ALL Show Reduced Accessibility
of the TCRa Locus
In the mouse, Ea is occupied by dedicated TFs from the
CD44loCD25+ (DN3) stage of thymocyte development onward,
well before transcriptional and recombinational activation of—
and, indeed, establishment of chromosomal accessibility at—
the TCR-Ja/Ca locus, arguing that Ea binding by TFs is dissoci-
ated from its functional activity (Herna´ndez-Munain et al., 1999;
Mauvieux et al., 2003; Spicuglia et al., 2000). In order to assess
the chromosomal status of the 30 part of the TCRa locus,
including Ea, in human TLX+ T-ALL, we used the formalde-
hyde-assisted isolation of regulatory elements (FAIRE) assay,
which allows the isolation of nucleosome-depleted (hence,
mainly accessible) genomic DNA regions (Giresi et al., 2007).
Using two primary TLX+ T-ALLs, we recovered large amounts
of Ea-overlapping chromosomal DNA, but the recovery of
upstream DNA sequences containing the TEA promoter or the
Ja58 or Ja28 segments was within the range observed for theunrelated T-ALL repressed genes PCDHGA12 and RPIB9 (Fig-
ure 1A and data not shown). In addition, quantification of the
expression by RT-qPCR demonstrated a drastic decrease
(100-fold on average) of Ca transcripts in TLX+ T-ALL
compared with TLX T-ALL (Figure 1B), corroborating microar-
ray data on gene-expression analysis of similar leukemia
samples (Ferrando et al., 2002). Finally, using chromatin-immu-
noprecipitation (ChIP)-on-chip assays we found that the
H3K27me3 mark, a hallmark of silent chromatin, is significantly
enriched in the TCR-Ja/Ca genomic region in TLX+ T-ALL
compared to TLX T-ALL (Figures 1C andS2). In contrast, similar
H3K27me3 profiles were observed in all T-ALL samples in the
repressed (GATA1; H3K27me3-enriched) or activated (GAPDH;
H3K27me3-depleted) control loci. Consistent with the FAIRE
data of nucleosomal depletion along Ea-containing sequences,
H3K27me3 enrichment in TLX+ T-ALL closely surrounded but
spared this discrete region. Overall, these findings imply that
the unrearranged TCR-Ja/Ca alleles typically found in TLX+
T-ALL blasts are poorly transcribed and most likely embedded
within repressive chromatin, despite localized accessibility of
Ea DNA. They further suggest that in the presence of TLX, Ea
is unable to confer chromosomal accessibility to the adjacent
genomic regions, notably the TCR TEA/Ja-containing region.
TLX1 and TLX3 Repress Ea Activity via Their
Homeodomain
To further test the possibility that the TLX1 and TLX3 proteins
interfere with Ea transcriptional activity, we used an Ea-depend-
ent reporter that expressed chloramphenicol acetyl transferase
(Ea-CAT). We found that ectopic expression of either GFP-
TLX1 or GFP-TLX3 repressed Ea-CAT expression by approxi-
mately 6-fold, and that this expression was partly rescued by
the co-expression of TLX1 or TLX3 siRNA, respectively (Fig-
ure 2A). We therefore evaluated the level of Ea-CAT repression
exerted by TLX1 and TLX3 mutants with or without their HD
(HD+ and HDdel, respectively), in reference to that of the corre-
sponding full-length (FL) proteins. As shown in Figure 2B, both
TLX1 HDdel and TLX3 HDdel exerted a reduced repressive activity
compared with their respective full-length (FL) proteins.
Conversely, TLX1 HD+ exerted an activity roughly equivalent to
FL TLX1, whereas TLX3 HD+ retained about half the repressive
effect of FL TLX3. We exclude the possibility that the reduced
repression activity by TLX1 HDdel and TLX3 HDdel was due to
their lack of nuclear localization by demonstrating that both
predominantly localized to the nucleus (Figures 2C and 2D).
We conclude that TLX1 and TLX3 repress Ea transcriptional
activity primarily in an HD-dependent manner.
TLX1 and TLX3 Exert Their Ea Repressive Activity
by Interacting with ETS1
The Ea-mediated transcriptional activity depends on the cooper-
ative binding of the ETS1 andRUNX1 TFs to Ea, together with the
lymphoid-specific HMG domain protein LEF1. To test whether
TLX1/TLX3-mediated Ea repression is ETS1, RUNX1, or LEF1
dependent, we repeated the reporter assays and removed
each TF individually. The fact that Ea-CAT expression was not
totally abolished in the absence of any one of these TFs (Giese
et al., 1995) makes it possible to quantify repression of the
residual activity after individual TF removal. In these conditions,Cancer Cell 21, 563–576, April 17, 2012 ª2012 Elsevier Inc. 565
Figure 1. TLX+ T-ALLs Show Reduced Accessibility of the TCRa Locus
(A) Graph showing formaldehyde-assisted isolation of regulatory elements (FAIRE) signals on two TLX+ T-ALL primary cell samples (UPN, unique patient number),
as assessed in using RT-qPCR and TEA, Ja58-, Ja28-, Ea-, or PCDHGA (a gene not expressed in T cells)-specific primers. Data represent means of duplicate
measurements whereby amplification signals were normalized to those of the corresponding input DNA with error bars to represent ±SD.
(B) Box plots for relative TCR-Ca gene expression normalized to housekeeping gene Abelson1 (ABL) in phenotypically matched TLX+ (n = 23) and TLX (n = 18)
T-ALLs, as assessed by RT-qPCR.
(C) Plots of ChIP-on-chip signals for H3K27me3 relative enrichment in two TLX+ and two TLX T-ALL cell samples. Black horizontal lines represent the no-change
lines. Black vertical bars indicate H3K27me3 peaks. The positions of the TCR-Ja, Ca, and Ea genomic regions, as well as those of exons and upstream promoter
sequences in the silent (GATA1) and expressed (GAPDH) control genes are indicated (exons depicted as vertical traits or black boxes). All four T-ALL samples
harbor at least one unrearranged TCRa allele (not shown).
See also Figure S2.
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TLX-ETS-Mediated TCRa Block of Maturation in T-ALLthe omission of ETS1 and, to a lesser extent, RUNX1, but not
LEF1, diminished TLX1/TLX3-mediated Ea-CAT repression
(Figure 2E). We also found that serial diminution of transfected
ETS1-expression vector led to a progressive decrease of
TLX/TLX3-mediated repression (Figure 2F). Altogether, our
data imply that TLX1/TLX3-mediated repression occurs mostly
via ETS1.
We therefore carried out in vitro GST-pull-down assays and
found that immobilized TLX1 and TLX3 retained the ETS1 FL
protein but not LEF1 (Figure 3A). The ETS1 DNA binding domain
(DBD) and the TLX1 and TLX3 HD-containing regions appeared
to be most important for this interaction (Figure 3A). We further
performed streptavidin precipitation experiments using HeLa
cells transfected with expressing vectors encoding ETS1-HA-
His, LEF1-HA, and TLX1- or TLX3-Flag-SBP tagged proteins.
Precipitation of TLX1/TLX3 only retained ETS1 but not LEF1
(Figure 3B). To confirm an interaction between endogenous
proteins, we carried out co-immunoprecipitation (Co-IP) using
TLX1+ ALL-SIL and TLX3+ DND41 cell lines and anti-TLX1 or
TLX3 monoclonal antibody (mAbs), which recovered both566 Cancer Cell 21, 563–576, April 17, 2012 ª2012 Elsevier Inc.ETS1 and the corresponding TLX in the precipitated material
(Figure 3C). Finally, we investigated the subcellular localization
of TLX1, TLX3, and ETS1 in TLX+ T-ALL clinical samples by
cell fractionation and immunostaining. Both analyses demon-
strated that TLX1, TLX3, and ETS1 localize in the nucleus
(Figures 4A and 4B). Moreover, both TLX+ and TLX T-ALL
expressed similar amounts of ETS1 protein and RNA (Figure 4A
and data not shown). Strikingly, the nuclear distribution of ETS1
was diffuse in TLX patient leukemic cells and cell lines (Fig-
ure 4B) but was irregular in TLX+ nuclei and overlapped signifi-
cantly with that of the TLX proteins (Figure 4C; see figure legend
for statistical information). Using ALL-SIL, we showed that, as
anticipated, the nuclear distribution of ETS1 became more
diffuse following TLX1 downmodulation (Figure 4D).
ETS1 Mediates TLX1 and TLX3 Recruitment
to Ea-Associated DNA Sequences
Given the data above in favor of an interaction between TLX1/
TLX3 and ETS1 proteins impinging upon Ea activity, we next






Figure 2. TLX1 and TLX3 Repress Ea-CAT Activity via Their Homeodomain
(A) Graph showing Ea-CAT fold repression in HeLa cells following transfection with GFP-TLX1FL or GFP-TLX3FL encoding vectors, with or without cotransfection
of the indicated small interfering (si) RNAs. Data represent means of triplicate measurements whereby Ea-CAT signals were normalized to those of control cells
transfected with a GFP vector, with error bars to represent ±SD.
(B) As in (A), but with HeLa cells transfected with GFP-TLXFL vectors alone, or with similar vectors carrying or lacking the corresponding TLX homeodomain (GFP-
TLX HD+ and GFP-TLX HDdel, respectively).
(C and D) Examples of fluorescence microscopic analysis of GFP-TLX expression in transfected HeLa cells depicted in (A) and (B). White scale bar is 10 mm.
(E) As in (A), but with HeLa cells transfected with GFP-TLXFL vectors, plus (+) or minus () additional vectors encoding the indicated ETS1, RUNX1, or LEF1 TFs.
(F) As in (E), but using decreasing amounts (200–10 ng) of ETS1-expression vector.
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TLX-ETS-Mediated TCRa Block of Maturation in T-ALLbinding sequences (EBS) of human Ea. Using electrophoretic
mobility shift assays (EMSA) we observed no significant shift of
the EBS probewhen incubatedwith TLX1/TLX3 alone (Figure 5A,
lanes 2–7). As expected, incubation with purified recombinant
ETS1 led to a major shift of the labeled probe (Figure 5B, lane
1). Strikingly, the addition of TLX1 (lanes 2–4) or TLX3 (lanes
5–7) to ETS1 and EBS produced a dose-dependent super-
shifted complex.
To ascertain Ea occupancy by endogenous TLX1 and TLX3
in vivo, we performed ChIP assays using ALL-SIL (TLX1+),
DND41 (TLX3+), and, as a control, RPMI-8412 (TLX) cell lines.
The ChIPed DNA was RT-qPCR amplified using Ea-specific
oligonucleotide primers and primers specific for the unrelated
Actin gene promoter (not bound by either ETS1 or TLX TF;
data not shown), used here as a mock control for data normali-zation. As expected, anti-ETS1 enriched Ea-associated
sequences from all three cell lines (Figure 5C). In contrast, anti-
TLX1 and anti-TLX3 enriched Ea-associated sequences from
only ALL-SIL and DND41, respectively, demonstrating in vivo
recruitment of TLX1 and TLX3 onto Ea. Using the DND41 and
ALL-SIL cell lines, we verified that knockdown of ETS1 reduced
Ea-binding by both ETS1 and TLX1/TLX3 (Figure 5D). Taken
together, these data indicate that TLX1 and TLX3 were recruited
to Ea via their interaction with ETS1 in TLX+ leukemic cells.
TLX Downmodulation and Enforced TCRab Expression
Both Lead to Redifferentiation Linked with Massive Cell
Apoptosis
Our results suggest that one of the major oncogenic functions of
TLX1/TLX3 in T-ALL would be to block ab T cell development byCancer Cell 21, 563–576, April 17, 2012 ª2012 Elsevier Inc. 567
AB
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Figure 3. TLX1 and TLX3 Interact with ETS1
(A) GST, GST-TLX1, and GST-TLX3 pull-down of
35S-labeled in vitro translated LEF1, ETS1, or
truncated versions of ETS1: ETS1DBD+, ETS1DBD,
ETS1TAD+PNT, and ETS1PNT. The various versions
of ETS1 are depicted on the right: PNT, pointed
domain; TAD, transactivation domain; DBD, DNA
binding domain. (Bottom) GST, GST-TLX HD+,
and GST-TLX HDdel pull-down of 35S-labeled
ETS1DBD+. TLX and its truncated forms are
depicted on the right: HD, homeodomain. The
‘‘Input’’ lanes correspond to 5% of the 35S-labeled
protein used for a pull-down experiment.
(B) Cell lysates from HeLa cells cotransfected with
vectors expressing ETS1-HA-His, LEF1-HA, and
TLX1-(or TLX3-) Flag-SBP were precipitated with
streptavidin (SP) beads and then immunoblotted
(IB) with either an anti-HA antibody (to reveal the
fusion proteins ETS1-HA-His and LEF1-HA), an
anti-His antibody (to reveal the ETS1-HA-His), or
an anti-Flag antibody (to reveal TLX and to eval-
uate SP efficiency). Input represents 10% of cell
lysate used for SP. FT, flow-through; LW, last
wash.
(C) Cell lysates from ALL-SIL and DND41 cells
were immunoprecipitated (IP) using anti-TLX1 (left)
or anti-TLX3 (right) antibody followed by immu-
noblotting with indicated antibodies. The ‘‘Input’’
lanes correspond to 10% of cell extracts used in
the Co-IP. No Ab, control IP experiment performed
without antibody; FT, flow-through; LW, last wash.
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knocked down TLX1 and TLX3 expression in ALL-SIL and
DND41 cell lines, respectively. While the control cells grew nor-
mally, the knockdown TLX1/ALL-SIL and TLX3/DND41 cells
demonstrated massive apoptosis (Figure 6A and 6B). Strikingly,
both Ca and TEA-Ca transcripts, as markers of TCR-Ja locus
activation (Herna´ndez-Munain et al., 1999; Monroe et al.,
1999), were upregulated in the TLX knockdown cells (Figure 6C).
Moreover, unlike transduced mock controls, the two TLX knock-
down cells harbored Va-Ja rearrangements, although with
a restricted polyclonal pattern, as expected (Figure 6D). The
knockdown cells further demonstrated a maturation shift, as
shown by increased cell size and CD5 expression (Figure 6E).
Most important, a small proportion of these cells became
sTCRab+ (Figure 6F).
We then assessed whether such a redifferentiation process,
including the triggering of cell death, could be induced by forced
expression of sTCRab, thus bypassing TLX/ETS1-mediated
suppression of Va-Ja rearrangement, in a TLX+/TCR T-ALL
cell line. TLX1+ ALL-SIL cells were transduced using lentiviral
multicistronic vectors enabling expression of GFP with or568 Cancer Cell 21, 563–576, April 17, 2012 ª2012 Elsevier Inc.without TCRb and TCRa (Figure 6G,
top). GFP+ sTCRab+ ALL-SIL cells ex-
hibited reduced viability and cell growth
compared to GFP+ sTCRab controls
when cultured in the OP9-DL1 stromal-
cell system (Figure 6G, bottom). This
correlated with increased apoptosis of
the sTCRab+ cells, as evidenced by pro-pidium iodide (PI)/annexin V dual staining (Figure 6H; note that
Jurkat cells carrying an identical sTCRab were not affected). It
is important to note that massive apoptosis was not observed
when transduced cells were cultured in a stromal-cell-free stan-
dard culture system (Figures 6G and 6H). These data demon-
strate the key role of TCR expression in mediating cell death in
TLX+ T-ALLs and strongly suggest that the apoptosis observed
upon TLX inhibition is a consequence of redifferentiation.
Overall, ectopic expression of TLX1/TLX3 in cortical thymo-
cytes appears to be required to maintain leukemic proliferation,
survival, and failure to differentiate; and defect in TCRab expres-
sion—via ETS1-mediated TLX recruitment onto Ea—is a major
mediator in oncogenic addiction, even after acquisition of
a variety of additional genetic abnormalities.
TCRa/d Translocations Occur 50 to TLX1 Leading
to Ea-Independent TLX1 Expression
While chromosomal translocations that lead to TLX3 deregula-
tion in T-ALLs virtually always involve genomic partners other
than TCRa/d (Bernard et al., 2001; Soulier et al., 2005), those




Figure 4. TLX1, TLX3 and ETS1Colocalize in
TLX+ T-ALL Blast Nuclei
(A) Western blot analysis of cytoplasmic (C) and
nuclear (N) extracts from TLX1+, TLX1+, and TLX
T-ALL cells. Blots were probed with anti-TLX and
anti-ETS1 antibodies as indicated.
(B) Confocal microscopy analysis of TLX T-ALL
and cell line (Jurkat) labeled with the indicated
fluorescent anti-ETS1 mAb (Alexa 647, red) or
stained by DAPI.
(C) Confocal microscopy analysis of the TLX+ T-
ALL and cell lines ALL-SIL (TLX1+) and DND41
(TLX3+) labeled with the indicated fluorescent anti-
TLX mAb (Alexa 488, green) and anti-ETS1 mAb
(Alexa 647, red), or stained by DAPI. The merged
images and overlapping areas (determined using
ImageJ software) are also shown. Pearson’s
coefficients for the overlapping areas were as
follows: r = 0,851 (UPN480); r = 0,608 (ALL-SIL); r =
0,929 (UPN364); and r = 0,816 (DND41).White
scale bars are 5 mm.
(D) As in (C), but the ALL-SIL cells were transduced
with TLX1-specific (TLX1 small-hairpin [sh]RNA) or
nonspecific (control shRNA) RNAs as indicated.
White scale bars are 5 mm.
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activity, as supported by the data above, how could Ea possibly
provide sustained TLX1 expression if it is juxtaposed to and
drives TLX1 expression? To get further insight into the mecha-
nism of TLX1 transcriptional activation, we first analyzed its
expression by RT-qPCR in 526 adult and pediatric T-ALLs and
identified 61 cases as TLX1+. We then identified TLX1 transloca-
tion into either the TCRd locus (35 cases) or the TCRb locus
(12 cases) in the 47 TLX1+ cases with enough material for
carrying out FISH- and/or ligation-mediated (LM) PCR analysis.
All informative cases tested for allelic transcripts (12 TCRd-
TLX1 and 2 TCRb-TLX1) demonstrated monoallelic TLX1
expression, in line with a ‘‘standard’’ regulatory element substi-
tution mechanism of oncogene deregulation in cis. We mappedCancer Cell 21, 563–5the breakpoints from 8 out of 12
TCRb-TLX1 alleles and 30 out of 35
TCRd-TLX1 alleles (Figure S3). While all
8 breaks from TCRb-TLX1 translocations
mapped 30 to TLX1, all 30 breaks from
TCRd-TLX1 translocations mapped 50 to
TLX1 (Figure 7A, top lane). Consequently,
whereas TLX1 activation in TCRb-TLX1
fusions was consistent with a classical
scenario of TCR-gene-enhancer-medi-
ated activation (in this case, the TCRb
gene enhancer Eb; Figure 7A, middle
lanes), the TCRd-TLX1 translocations
separated the TLX1 gene and Ea element
on the two derivative chromosomes (Fig-
ure 7A, bottom lanes), implying Ea-inde-
pendent activation and/or maintenance
of TLX1 oncogenic expression.
To investigate whether TLX1 overex-
pression resulted from its juxtapositionto a cis-regulatory element(s) within and/or upstream to the
TCRd promoter, we performed clonospecific RT-PCR across
the breakpoints of both TCRd-TLX1 and TCRb-TLX1 transloca-
tions. Given the structure of these translocations, the detection
of fusion transcripts in all the TCRd-TLX1 samples, but not in
the TCRb-TLX1 samples (Figure 7B), was consistent with the
presence of a positive regulatory element(s) within and/or
upstream to the TCRd locus that drives TLX1 overexpression.
Ea Repression Results in a TLX1 Feed-Forward
Repression Loop
Despite the obvious difference in the origin of TLX1 transcrip-
tional activation in TCRb versus TCRd translocations, we ob-
served no significant disparity in their levels of TLX1 expression76, April 17, 2012 ª2012 Elsevier Inc. 569
AC
D
B Figure 5. ETS1 Mediates TLX1 and TLX3
Recruitment to Ea-Associated DNA Se-
quences
(A) EMSA of the 32P-labeled EBS oligonucleotide
probe comprising core Ea nucleotide sequences
(Giese et al., 1995) with purified recombinant GST-
TLX1 and GST-TLX3 proteins. Lane 1, free EBS
probe; lanes 2–4 and lanes 5–7 EBS incubated
with increasing amounts (10, 50, and 100 ng) of
GST-TLX1 or GST-TLX3, respectively; lane 8, EBS
incubated with 100 ng of GST.
(B) As in (A), but with the presence of 20 ng of
purified recombinant ETS1 protein (lanes 1–7) and
ETS1 with increasing amounts (10, 50, and 100 ng)
of GST (lanes 8–10).
(C) Graphs of ChIP signals for Ea from the ALL-SIL
(TLX1+), DND41 (TLX3+), and RPMI (TLX) cell
lines using anti-ETS1, anti-TLX1, and anti-TLX3
antibodies, as indicated. ChIPed DNA was qPCR
amplified using Ea and actin (negative-control)-
specific oligonucleotide primers. Enrichment level
was determined by comparison to a standard
curve from input DNA. ChIPed signal enrichments
correspond to the ratios between the Ea signal
and actin signal. IgG isotype control was per-
formed to assess absence of nonspecific Ea ChIP
enrichment (not shown). Data represent means
of triplicate measurements with error bars to
represent ±SD.
(D) As in (C), but with the ALL-SIL and DND41cells
transduced with ETS1-specific or nonspecific
shRNAs. Shown beneath the graph are western
blots for ETS1 or actin expression from mock
transduced (shRNA control) and knockdown
(shRNA ETS1) cells.
Cancer Cell
TLX-ETS-Mediated TCRa Block of Maturation in T-ALL(data not shown). This may reflect oncogenic selection of only
those rearrangements with sufficient/optimal TLX1 expression.
We also searched for possible differences in the stage of matu-
ration arrest and/or kinetics of TLX1 activation. TLX1+ T-ALLs are
commonly arrested at a cortical TCRab negative stage of matu-
ration (Ferrando et al., 2002). In keeping with this, all TLX1+
T-ALL cases (whether TCRd or TCRb translocated) display
a uniform cortical CD1a+/CD34neg phenotype (Asnafi et al.,
2003; Ferrando et al., 2002). Furthermore, sequence analysis
demonstrated that both TCRd and TCRb translocations
occurred at a similar stage of early thymic-cell differentiation
with respect to rearrangement events, since all TCRd- and
TCRb-TLX1 junctions resulted from repair mistakes introduced
during, respectively, a Dd2-Dd3 (or Dd3-Jd1) rearrangement, or
a Db-Jb rearrangement (Figure S3). These data further implied
that TLX1 oncogenic activation uniformly took place at an imma-570 Cancer Cell 21, 563–576, April 17, 2012 ª2012 Elsevier Inc.ture DN/CD1a/CD34+ stage of thymic
cell development, while cell maturation
arrest occurred at a later (cortical) stage.
We therefore hypothesized that 30
TCRd-TLX1 translocations do not under-
go oncogenic selection because of a
feed-forward inhibitory effect exerted by
TLX1 itself, inducing autorepression of
Ea transcriptional activity. This wouldinfer that TCRa/d driven translocations with 30 TLX1 breakpoints
could occur but would fail to be selected within an oncogenic
context. As several examples of potentially oncogenic TCR
translocations have previously been reported in healthy thymi
(Dik et al., 2007; Marculescu et al., 2003, 2006), we searched
normal thymus for putative TCRd-TLX1 translocations with
breakpoints involving either side of TLX1 (Figure 7C, top lanes).
We set up a highly sensitive double-nested qPCR allowing the
recovery of rare translocation events (108109) and applied
this assay to screen the DNA equivalent of 109 thymocytes
from 10 healthy postnatal thymi. Even though no 50 type junction
was observed, two 30 type junctions were reliably detected (Fig-
ure 7C, bottom lanes). This demonstrates that 30 type TCRd-
TLX1 translocations do occur in the normal thymus and are at
least no less common than 50 translocations. Themain difference
between the 30 TCRb-TLX1 translocations observed in T cell
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TLX-ETS-Mediated TCRa Block of Maturation in T-ALLleukemias and the 30 TCRd-TLX1 exclusively found in nonleuke-
mic thymi consists in their association with the Eb or Ea element,
respectively. Given the aforementioned inhibition of Ea activity
by TLX1, these data support the intriguing possibility that
deregulation of TLX1, when driven by Ea, will lead not to onco-
genic selection but rather to autonomous counterselection of
the chromosomal translocation due to feed-forward repression
(Figure 7D).
DISCUSSION
HOX proteins in general, and TLX in particular, exert a repressive
activity on transcriptional events during embryonic development
(Mann et al., 2009; Merabet et al., 2005; Owens et al., 2003; Shen
et al., 2001). Our study identifies TCR Ea as a target for such
a repressive activity upon ectopic expression in T cell develop-
ment, offering molecular insight into the stage of maturation
arrest and oncogenesis of TLX+ T-ALLs.
The onset of V(D)J recombination is primarily regulated at the
level of chromatin and access of the RAG1/RAG2 recombinase
apparatus to its DNA targets, a process that depends on the
activity of transcriptional enhancers in TCR and Ig loci, including
Ea and Ed in the TCRa/d locus (Krangel et al., 1998). Our data
pinpoint a suppressive chromatin configuration around Ea and
amolecular explanation to the strong bias against Va-to-Ja rear-
rangement observed in TLX+ T-ALLs. The TCRa repressed struc-
ture appears to specifically affect the TEA/Ja-containing region,
since in cases where unrearranged TCRa/d alleles could be
analyzed for H3K27me3, the proximal, 30 part of the TCR-Va
locus behaved similarly in TLX+ and TLX blasts (Figure S2).
Although proximal Va segments lie within the range of long-
distance chromatin regulation by Ea, an active, derepressed
chromatin configuration would be expected at these sequences
in early cortical thymocytes due to the activity of the nearby Ed
(Hawwari and Krangel, 2005). In short, the aberrant TCRa/d
recombination patterns seen in TLX+ T-ALL faithfully mirror the
chromatin opening function that exclusively relies on Ea.
We have identified the ETS1 TF as a mediator, via protein-
protein interaction, of this Ea-suppressing function of TLX1/
TLX3. There is precedent for inhibition of a cell-developmental
pathway by ETS1, MafB-ETS1 interaction having been reported
to result in a block to erythroid differentiation (Sieweke et al.,
1996). The precisemechanisms for the repression by TLX remain
to be elucidated, but our current data provide interesting clues.
Recruitment of both TLX and ETS1 onto Ea render unlikely
a basic model whereby TLX sequesters ETS1 away from the
enhanceosome; however, more complex, locally induced,
opposing molecular switches dependent on the nature of
ETS1-interacting TF partners could not be excluded (Sieweke
et al., 1996). Likewise, our unpublished findings that TLX1/
TLX3 still suppresses transcription on cell treatment with
a histone deacetylase (HDAC) inhibitor suggest that HDAC is
not involved. The creation of a distinct heterochromatin-
promoting complex is plausible, since HOX proteins have been
shown to fix polycomb (PcG) repressive components (Papp
and Mu¨ller, 2006). Our finding of H3K27me3 enrichment along
Ea-flanking genomic regions in TLX+ T-ALL supports this, as
H3K27me3, in addition to being a marker of repressive chro-
matin, is associated with activity of the PcG complex PRC2(Sauvageau and Sauvageau, 2008). This suppressive function
for TLX on Ea activity via ETS1 does not exclude protein-protein
interaction with and mediation of a suppressive effect by, other
TFs, such as RUNX1 (Hollenhorst et al., 2009).
ETS1 plays an important role in cell developmental controls
and neoplastic processes (Dittmer, 2003). TLX1/TLX3 overex-
pressionwould therefore be expected to deregulatemultiple bio-
logical networks via its interaction with ETS1. The TLX1/TLX3-
ETS1-mediated Ea inhibition described here unlikely would
explain the whole T-ALL oncogenic program induced by TLX1/
TLX3, since Ea deletion in mice has not been associated with
the development of T cell leukemia (Sleckman et al., 1997) and
transgenic TLX1-driven murine leukemias demonstrate a variety
of somatic genetic abnormalities (De Keersmaecker et al.,
2010). TLX1/TLX3-ETS1-mediated Ea inhibition, however, likely
accounts for the early cortical block in cell maturation around
b-selection characteristic of these leukemias.
Inactivation of ETS1 impairs, but does not abolish, the devel-
opment of DN3 thymic cell differentiation into DP cells and the
defect appears to be specific to the ab T cell lineage, as gd
T cells mature normally (Eyquem et al., 2004). In line with this,
TLX+ T-ALLs often express a TCRgd, albeit in conjunction with
the cytoplasmic TCRb chain. In this context, it is noteworthy
that, despite the presence of ETS1 and RUNX binding sites
within Eb, ETS1 deficiency did not affect Eb activity (Eyquem
et al., 2004), pointing to different requirements for the activity
of Eb and of Ea. As mentioned, an alternative and non-mutu-
ally-exclusive candidate for mediation of the maturation arrest
might be BCL11b, recently reported to be a direct target down-
regulated by TLX1 (De Keersmaecker et al., 2010). Loss of
BCL11b, a transcriptional repressor required for T lymphoid
specification, leads, however, to a much earlier DN1/2 block
(Ikawa et al., 2010; Li et al., 2000, 2004). Our data would suggest
that abrogation of ETS1 activity on Ea is more likely than loss of
BCL11b to explain the cortical arrest seen in human T-ALLs. As
in vivo confirmation of the capacity of TLX1 to inhibit Ea-enhan-
ceosome-driven transcription, we also show here that TCRd-
TLX1 genomic products resulting from a t(10;14) translocation
will lead to either a cell-maturation arrest and leukemogenesis
or autoextinction of translocated clones, depending on the
configuration of the translocation breakpoints. One interesting
aspect of the autoextinction model is that in order to efficiently
repress its own sustained expression in-cis, the TLX1 protein
has to be produced prior to disrupting activity of the Ea enhan-
ceosome on the TLX1-TCRd/Ea translocated allele (Figure 7C).
If so, it seems reasonable to assume that the same repression
also occurs in-trans on the normal (nontranslocated) TCRa allele,
leading to inhibition of TCRa rearrangement and a block in
thymocyte differentiation. The fact that these cells do not
undergo malignant transformation implies that sustained (and/or
higher-level) TLX1 expression is required for leukemic transfor-
mation. Such a TLX1 ‘‘oncogene addiction’’ argues in favor of
TLX1 being the initiating and causative oncogenic event in
TLX1+ T-ALL cases. This model obviously does not exclude
oncogenic synergy with other abnormalities.
In line with a major role of ETS1/TLX-mediated repression of
Ea in this TLX-induced oncogenic addiction, knockdown of
TLX1/TLX3 led to apoptosis, concomitant TCRa transcription
and rearrangement, cell-maturation, and sTCRab+ expressionCancer Cell 21, 563–576, April 17, 2012 ª2012 Elsevier Inc. 571
Figure 6. Abrogation of the T Cell Maturation Block Induces Cell Death
(A) Western blots for expression of TLX1 (top left), TLX3 (top right), and the actin control (bottom) in ALL-SIL and DND41 cells transduced with specific or
nonspecific (control) shRNA. The graph shows cellular growth at days (D) 3, 6, 9, and 12 of cell culture.
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TLX expression is required for maintenance of leukemic cell
survival and blocked differentiation, and that both may be intri-
cately linked. The fact that the apoptotic effect of TLX1 abroga-
tion was mimicked by transducing a TCRab transgene in TLX1/
ALL-SIL cells in the presence, but not in the absence, of stroma
supports these conclusions. Thus, as predicted from a bypass of
the ETS1/TLX-mediated Ea inhibitory control, both enforced
sTCRab expression leading to exit from b-selection and TLX
abrogation lead to a similar outcome (i.e., apoptosis). Different
outcomes (cell death versus proliferation) depending on the
presence or absence of OP9-DL1 stroma are likely to reflect
a role for stromal (or other ligand) interaction in cell death
following TCRab expression and differentiation. In general,
T cell responses require costimulation-engagement of the clono-
typic TCR together with that of distinct coreceptors and cognate
ligands. Our current findings offer a unique opportunity to
explore such a partnership in TLX+ T-ALL tumorigenesis in
prospective studies.
Taken together, our results demonstrate that the maturation
block observed in TLX+ T-ALLs is in large part due to ETS1-medi-
ated TLX recruitment to the Ea core, leading to repression of Ea
and blocked Va-Ja rearrangement. Failure to express a TCRa
gene arrests development of ab-committed thymocytes around
b-selection, when a variety of cell-proliferation signals are likely
to be maintained, hence contributing to oncogenesis. This
blockage can be overcome by TLX1/3 abrogation or by down-
stream TCRab expression within an appropriate cellular context.
These observations have fundamental consequences both for
targeted therapy in TLX+ T-ALLs and for the role of aberrant
TCR expression in T lymphoid oncogenesis.
EXPERIMENTAL PROCEDURES
Full Experimental Procedures and any associated references are available in
the Supplemental Experimental Procedures.
Patient Analysis and Clinical Diagnosis
Diagnostic samples of peripheral blood or bone marrow from T-ALL patients
included in the GRAALL or FRALLE protocols were investigated. Approval
was obtained from institutional review boards of institutions participating in
this study; the full list of participating centers is given in Supplemental Exper-
imental Procedures. The age cut-off between pediatric and adult cases was 18
years. All samples contained R80% blasts. Informed consent was obtained
according to the declaration of Helsinki. DNA and RNA extraction and identi-(B) Flow cytometric analysis of TLX1+ ALL-SIL cells following transduction with re
specific shRNAs. GFP+-transduced cells were gated for analysis of AnnexinV/PI
(C) RT-qPCR quantification of Ca and TEA-Ca transcripts in ALL-SIL/DND41 follo
transcript levels are shown relative to those of ABL control transcripts (**p value
(D) Multiplex RT-PCR analysis of Va-Ja-Ca rearrangements from ALL-SIL (left) a
to fourth panel pairs) shRNA transduction and 9 days of cell culture. Normal T
Va-Ja-rearranged PCR fluorescent products, as found in normal PBLs (bottom).
(E) Histograms of forward scatter and CD5 mean of fluorescence of GFP+ ALL-S
represent ±SD. ***p% 0.001, Student test.
(F) Flow cytometric analysis of GFP+ ALL-SIL cells for CD3 and TCRab surface e
(G) Kinetics of CD3 and TCRab surface expression (top left), and cell viability an
without transduction of TCRab cDNAs and with or without OP9-DL1 stromal cult
cells is also shown (top right).
(H) Top andmiddle cytographs are as in (B), but with the ALL-SIL cells treated as in
Jurkat cells are shown as TCRab+ TLX1 controls cultured in identical conditionfication of TCRd, TCRg, and TCRb clonal rearrangement were identified as
described (Asnafi et al., 2003).
CAT-Reporter Assays
CAT-transactivation assays were performed as described (Giese et al., 1995).
Streptavidin Precipitations and Immunoprecipitations
HeLa cells were cotransfected using expression vectors for ETS1-HA-His,
LEF1-HA, and either TLX1-SBP-Flagx3 or TLX3-SBP-Flagx3, or the empty
expression vector SBP-Flagx3 as a control. ALL-SIL (TLX1+) and DND41 SIL
(TLX3+) cells were used for protein IPs. Nuclear extracts were prepared and
incubated with streptavidin agarose beads or with anti-TLX1 (16F6) or anti-
TLX3 (10A5) mAbs, respectively, covalently linked to protein G agarose beads.
After washes, precipitated proteins were detected by western blot analysis.
Fluorescence and Immunofluorescence Analyses
For EGFP fluorescence analysis, HeLa cells plated on coverslips were tran-
siently transfected with EGFP-fusion constructs and further cultured for
48 hr. Imaging was performed using a Zeiss (LSM-510) confocal microscope.
For immunofluorescence analysis, cell lines or primary blast cells (1 3 105)
were cytospun onto glass slides. Images were obtained on a Leica TCS SP5
confocal laser scanningmicroscope andmerged using Leica LAS AF software.
Chromatin Immunoprecipitation
ChIPs from the ALL-SIL, DND41, and RPMI cell lines or from T-ALL samples
were performed according to the Agilent protocol version 10.0 (http://www.
chem.agilent.com), using anti-TLX1 (16F6), anti-TLX3 (10A5), anti-H3K27me3
(05851, Abcam), and anti-ETS1 (sc-350, C-20X, Santa Cruz) mAbs.
TLX1 and TLX3 Knockdown
MISSION TRC shRNA Target Set vectors for TLX1 (TRCN0000014995), TLX3
(TRCN0000018030), and ETS1 (TRCN0000231917) were purchased from
Sigma. Knockdown of the corresponding endogenous RNA transcripts was
performed by transduction of the ALL-SIL and DND41 cell lines.
Screening for TCR-TLX1 junctions
Screening for 30 type t(10;14)(q24;q11) translocations was performed using
pooled thymocytes from 10 healthy children undergoing cardiac surgery.
ACCESSION NUMBER
The ChIP-on-chip data have been deposited at ArrayExpress (http://www.ebi.
ac.uk/arrayexpress/) with the accession number E-MEXP-3527.
SUPPLEMENTAL INFORMATION
Supplemental Information includes one table, three figures, and Supplemental
Experimental Procedures and can be found with this article online at doi:10.
1016/j.ccr.2012.02.013.troviruses encoding the GFP protein and either control (nonspecific) or TLX1-
staining.
wing shRNA (TLX-specific versus mock control) transduction. Ca and TEA-Ca
% 0.01; ***p value% 0.001), with error bars to represent ±SD.
nd DND41 (right) cDNA, following mock control (top) or TLX-specific (second
CRab rearranged repertoires give a Gaussian distribution of variable length
Abrogation of TLX1/TLX3 allows a variety of Va-Ja rearrangements.
IL cells assessed by flow cytometry, following shRNA transduction. Error bars
xpression.
d growth (bottom), analyzed for GFP+ cells in the indicated cell lines, with or
ure conditions. RT-qPCR analysis for TLX1 transcription in Jurkat and ALL-SIL
(G). Bottom cytographs are as in (F), but with the ALL-SIL cells treated as in (G).
s.
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Figure 7. Molecular Analysis of TCRb-TLX1 and TCRd-TLX1 Translocations
(A) Top lane, schematic representation of the TLX1 locus (10q24). Arrowheads and arrows indicate the relative positions of breakpoints in TCRb- and TCRd-TLX1
translocations, respectively; middle and bottom lanes, representations of TCRb- and TCRd-TLX1 typical translocations. Thick and thin lines depict the 10q24 and
7q34 chromosomal regions, respectively (sequences of the TCR-TLX breakpoint junctions are reported in Figure S3).
(B) TCRd-TLX1 translocations, but not TCRb-TLX1 translocations, generate TCR-TLX fusion transcripts. Fusion sequences resulting from TCRd-TLX1 trans-
locations (left) or TCRb-TLX1 translocations (right) are depicted and PCR primers indicated for 150 ng of cDNA amplified using TLX1-specific primers (lane 1), 15,
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